Antibacterial efficacy of core-shell nanostructures encapsulating gentamicin against an in vivo intracellular Salmonella model by Ranjan, A. et al.
Campbell University 
CU FIND 
Osteopathic Medicine, Jerry M. Wallace School 
of Faculty Research and Publications 
2009 
Antibacterial efficacy of core-shell nanostructures encapsulating 
gentamicin against an in vivo intracellular Salmonella model 
A. Ranjan 
N. Pothayee 
M. N. Seleem 
R. D. Tyler 
B. Brenseke 
See next page for additional authors 
Follow this and additional works at: https://cufind.campbell.edu/medicine_school 
 Part of the Medicine and Health Sciences Commons 
Authors 
A. Ranjan, N. Pothayee, M. N. Seleem, R. D. Tyler, B. Brenseke, N. Sriranganathan, J. S. Riffle, and R. 
Kasimanickam 
© 2009 Ranjan et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
International Journal of Nanomedicine
International Journal of Nanomedicine 2009:4 289–297 289
Dovepress
open access to scientific and medical research
Open Access Full Text Article
submit your manuscript | www.dovepress.com
Dovepress 
O R I g I N A L  R e s e A R c h
Antibacterial efficacy of core-shell nanostructures 
encapsulating gentamicin against an in vivo 
intracellular Salmonella model
Ashish Ranjan1 
Nikorn Pothayee2,3 
Mohammed N seleem2 
Ronald D Tyler Jr4 
Bonnie Brenseke4 
Nammalwar sriranganathan2,4
Judy s Riffle2,3
Ramanathan Kasimanickam1
1Department of Large  Animal clinical 
sciences, 2Institute for critical 
Technology and  Applied science, 
3Macromolecules and Interfaces 
Institute, 4Department of Biomedical 
sciences and Pathobiology,  Virginia 
Polytechnic Institute and state 
University, Blacksburg,  VA
correspondence: Nammalwar 
sriranganathan 
Department of Biomedical sciences and 
Pathobiology,  Virginia Polytechnic Institute 
and state University Blacksburg VA, UsA 
Tel +1 540 231 7171 
email nathans@vt.edu
Abstract: Pluronic based core-shell nanostructures encapsulating gentamicin were designed 
in this study. Block copolymers of (PAA–+Na-b-(PEO-b-PPO-b-PEO)-b-PAA– +Na) were 
blended with PAA– Na+ and complexed with the polycationic antibiotic gentamicin to form 
nanostructures. Synthesized nanostructures had a hydrodynamic diameter of 210 nm, zeta 
potentials of –0.7 (±0.2), and incorporated ∼20% by weight of gentamicin. Nanostructures upon 
co-incubation with J774A.1 macrophage cells showed no adverse toxicity in vitro. Nanostructures 
administered in vivo either at multiple dosage of 5 µg g–1 or single dosage of 15 µg g–1 in AJ-646 
mice infected with Salmonella resulted in significant reduction of viable bacteria in the liver 
and spleen. Histopathological evaluation for concentration-dependent toxicity at a dosage of 
15 µg g–1 revealed mineralized deposits in 50% kidney tissues of free gentamicin-treated mice 
which in contrast was absent in nanostructure-treated mice. Thus, encapsulation of gentamicin 
in nanostructures may reduce toxicity and improve in vivo bacterial clearance.
Keywords: gentamicin, core-shell nanostructures, Salmonella
Introduction
Delivery systems capable of transferring cell-impermeable drugs into cells have 
tremendous potential for improving therapeutic efficacies in vivo.1 In the last few 
decades, nanotechnology has been increasingly employed in new drug delivery systems 
(DDS). DDS developed through nanotechnology may allow for reductions in dosage 
and dosage frequency and may also prevent toxicity associated with conventional 
therapy. This may be especially beneficial for chronic intracellular infections which 
now require long-duration combination therapies.2 For example, aminoglycosides are 
a common class of antibiotics utilized clinically for treating bacterial infections. They 
have broad activities against both Gram-negative and Gram-positive bacteria.3 However, 
the action of aminoglycosides is concentration-dependent and free gentamicin filters 
rapidly through the renal system, thus necessitating high dosages. Administration of 
high dosages of aminoglycosides may result in nephrotoxicity and ototoxicity, which 
may be prevented with nanomedicine-based therapy.4
To achieve intracellular delivery of aminoglycosides, several drug delivery 
strategies have been utilized including liposomes and polymeric carriers.5,6 These drug 
delivery systems have improved the intracellular delivery of aminoglycosides, but 
suffer from low drug incorporation. Core-shell drug delivery systems have recently 
attracted considerable attention due to their unique ability in encapsulating charged 
therapeutic molecules.2 The unique ability is conferred to the core-shell structures 
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mainly by fabricating the core to contain high amounts of 
ionic species and tailoring shell with specific hydrophobic/
hydrophilic chemistry as shown schematically in Figure 1. 
This may result in encapsulation of high payload of oppositely 
charged ionic species like gentamicin inside the cores and 
successful interaction of the shell’s hydrophobic segment 
with the cell membranes.
We previously reported synthesis of core-shell nanostruc-
ture with amphiphilic shell containing pluronic F68 which 
can incorporate up to ∼25% by weight of gentamicin and their 
in vitro trafficking and efficacy in infected macrophage cells.22 
Pluronics have widely been used as excipients in pharma-
ceutics.7 Pluronic triblock copolymers are comprised of 
hydrophilic poly(ethylene oxide) (PEO) terminal blocks with 
a hydrophobic poly(propylene oxide) (PPO) central block 
(ie, PEO-b-PPO-b-PEO) in a basic A-B-A structure: EO
x/2
-
PO
y
-EO
x/2
.8 Different pluronic copolymers are characterized 
distinctly by their hydrophilic-lipophilic balance (HLB). 
For example, the HLB of pluronic F68 is 29 whereas that 
of pluronic P85 is 16. Therefore, pluronic F68 is relatively 
less hydrophobic than pluronic P85. Pluronics have been 
investigated extensively for cancer chemotherapy of multi-
drug resistant (MDR) tumors.9 By varying the lengths of the 
hydrophobic propylene oxide (y) and hydrophilic ethylene 
oxide (x) segments, increased potency and intracellular 
uptake of the DDS were seen in the tumor cells.10 Studies on 
KBv cell lines have shown that the accumulation of pluronics 
inside the cells is dependent on HLB. In general, pluronics 
with HLB of 20–29 had minimal effect on drug transport. 
In contrast, pluronics with HLB less than 20 exhibited 
varying degree of activity against MDR cells.8 Thus, the 
triblock arrangement provides an advantage of altering 
the hydrophilic/hydrophobic balance to suit a particular 
therapeutic application.11 Therefore, its incorporation in DDS 
for cell specific therapy may be highly favorable,12 especially 
for intracellular infections.
Preclinical studies conducted previously with biodegradable 
DDS made from a combination of poly(ε-caprolactone) (PCL) 
and Pluronic F68 did not cause any adverse toxicological 
response in rats or dogs.18 In this study, we designed core-
shell nanostructure by synthesizing PAA– +Na-b-PEO-b-PPO-
b-PEO-b-PAA– +Na block copolymers and complexed them 
with gentamicin to form nanostructures with PEO-b-PPO-b-
PEO shells, and PAA cores containing the antibiotic shown 
schematically in Figure 1. The efficacies of these core-shell 
nanostructures were investigated in an in vivo intracellular 
Anionic block copolymers Aminoglycosides
Inonic condensation
Hydrophobic segment Hydrophilic segment
Amphiphilic core-shell complexes
Figure 1 Schematic illustration of methodology for preparing core-shell nanostructure encapsulating gentamicin.
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Salmonella mouse infection model. Our objectives also 
included an evaluation of the observed reduction in gentami-
cin toxicity that resulted from encapsulation in the cores.
Materials and methods
Materials
All chemicals were purchased from Sigma-Aldrich unless 
otherwise noted. t-Butyl acrylate (tBA) was distilled from 
calcium hydride under vacuum prior to polymerization. 
Pluronic F68 (M
n
 ∼8,300 g mol–1) was kindly provided by 
BASF (NJ, USA). Pluronic F68 and polyethylene oxide 
monomethyl ether (M
n
 ∼2,000 g mol–1) were dried under 
vacuum at 70°C for 48 hours prior to any polymerizations.
Preparation of core-shell nanostructures 
loaded with gentamicin
Block copolymers of poly(sodium acrylate)-(PEO-b-PPO-
b-PEO)-poly(sodium acrylate) (PAA– +Na-(PEO-b-PPO-
b-PEO)-PAA– +Na) and PEO-PAA- +Na were prepared 
according to a previously published procedure.13 Briefly, 
PEO-b-PPO-b-PEO (Pluronic F68) with hydroxyl terminal 
groups was derivatized with 2-bromoisobutyryl bromide 
to provide bromoalkyl functional endgroups and then 
t-butyl acrylate was polymerized by controlled atom trans-
fer radical polymerization (ATRP). The protective t-butyl 
groups were subsequently removed with trifluoroacetic acid 
and the polymer was neutralized with NaOH to form the 
sodium salt (PAA- +Na-(PEO-b-PPO-b-PEO)-PAA- +Na). In 
a 100-mL round-bottom flask, 34 mg of PAA- +Na-(PEO-
b-PPO-b-PEO)-PAA- +Na (1.90 × 10-4 eq of anions) and 
16 mg of PAA- +Na (1.6 × 10–4 eq of anions) were dissolved 
in 50 mL of DI water and the pH was adjusted to 7 with 
NaOH (1 N). The solution was placed in a sonication bath 
and 5 mL of gentamicin sulfate solution (10 mg mL-1 gen-
tamicin sulfate, equal to 30 mg gentamicin, 3.5 × 10-4 eq of 
cations) was added via syringe to form a turbid dispersion. 
Any non-complexed free gentamicin sulfate was removed 
by dialysis against 4 L of deionized (DI) water at 4°C for 
24 hours and the core-shell nanostructures were recovered 
by freeze-drying. Core-shell nanostructure prepared by this 
methodology was later utilized for in vivo treatment efficacy 
studies at dosage of 5 µg g–1 and 15 µg g–1 respectively. The 
nomenclature describing the mice treated at 5 µg g–1 adopted 
for this paper is D1 (D1N for the group treated with core-
shell nanostructure and D1G for the group treated with free 
gentamicin alone). Similarly, the mice administered with 
15 µg are designated as D2 (D2N for the group treated with 
the core-shell nanostructure and D2G for mice group treated 
with free gentamicin alone).
characterization of complexes
The solute sizes and zeta potentials of the complexes were 
characterized by DLS with a Zetasizer 1000 HS with laser 
diffractometry (Malvern Instruments, Malvern, UK) at a 
scattering angle of 90o. Each complex (1 mg) was dispersed 
in 1 mL of DI water and analyzed. Measurements were done 
in triplicate for each batch of particles. The results were taken 
as the average of three measurements.
gentamicin concentration  
in the nanostructure
The amount of gentamicin loaded into the core-shell 
nanostructures was determined via an o-phthalaldehyde 
assay according to a previously published procedure.14 
To quantify the amount of encapsulated gentamicin, the 
complexes were dissolved in borate buffer at pH 9.7 to 
disintegrate the particles and release the drug in the free 
amine form. The primary amine on gentamicin was then 
reacted with an excess of phthalaldehyde in the presence of 
mercaptoethanol to produce a derivative that was quantified 
via UV-visible spectroscopy. For derivatization, gentamicin 
solution, phthalaldehyde reagent containing mercaptoethanol, 
and isopropanol (to avoid precipitation of the products) 
were reacted for 30 minutes at room temperature, and the 
absorbance of the product was measured at 335 nm.
In vitro MTs toxicity assessment
An in vitro homogeneous, colorimetric CellTiter 96® 
AQueous Non-Radioactive Cell Proliferation MTS (3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium) Assay (Promega Corporation) 
for determining the numbers of viable J774A.1 cells was 
utilized to determine any cytotoxicity of the polymers and 
the nanostructures. Briefly, ∼2 × 104 J774A.1 cells suspended 
in 200 µL of DMEM supplemented with 10% fetal bovine 
serum (FBS), L-glutamine, NaHCO
3
, pyridoxine-HCl, and 
4.5% glucose and preserved with 1% penicillin-streptomycin 
solution were seeded in 96-well plates and incubated for 
24 hours at 37°C in a 5% CO
2
 atmosphere. The J774A.1 cells 
were further incubated with 250 µg/mL of free gentamicin, 
copolymer, core-shell nanostructures encapsulating 
gentamicin along with the appropriate untreated control 
for 24 hours. The culture media was discarded, and the 
cells in each well were washed with PBS and re-suspended 
with 100 µL of cell culture media. Then 20 µL of CellTiter 
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96® AQueous reagent solution was pipetted into each well, 
and the plates were incubated for 4 hours at 37°C in a humidi-
fied 5% CO
2
 atmosphere. The absorbance at 490 nm was 
recorded using a 96-well Elisa plate reader (SoftMax Pro 
Inc., USA). Results were expressed as the percentage mean 
absorbance by cells upon incubation with various treatments 
(nanostructure, copolymer or free gentamicin) with respect 
to incubation in untreated control.
In vivo toxicity
To assess concentration/dose dependent toxicity, kidney 
tissue from the untreated, D2N- or D2G-treated mice were 
harvested and assessed for histopathological changes. 
The kidneys were fixed in 10% neutral buffered formalin, 
routinely processed into paraffin blocks, and 5 micron 
sections were stained with hematoxylin and eosin on glass 
slides (Virginia-Maryland Regional College of Veterinary 
Medicine, Veterinary Teaching Hospital). Tissue samples 
were examined independently by light microscopy and 
scored by two veterinary pathologists. The pathologists were 
blinded to obtain unbiased assessment. The kidneys were 
scored on a scale of 0 to 4 based on the degree of inflamma-
tion as reported before.15,16 Briefly, a semi-quantitative scale 
of change consisting of whole numbers with scores from 
0 to 4 was given as (0) = unremarkable, (1) = minimum, 
(2) = mild, (3) = moderate, and (4) = marked. Changes include 
inflammation (infiltration of inflammatory cells), necrosis 
(morphologic changes of renal parenchyma cells consistent 
with degeneration and necrosis) and vascular disruptions 
(hemorrhage, edema and other signs of vascular leakage). 
The percentage of affected section of tissue being affected is 
what was used to score any change viz. 0% = unremarkable 
(0), 0% to 5% = minimal (1), 6% to 10% = mild (2), 11% 
to 20% = moderate (3), 20% = marked.4 Furthermore, any 
samples with the presence of mineral deposits associated 
with regions of inflammation were assigned an additional 
0.5 points to take mineralization into account for final 
analysis.
Treatment efficacy of core-shell 
nanostructures against against 
S. typhimurium
S. enterica typhimurium (wild type) was grown overnight 
in Luria-Bertani (LB) broth, centrifuged, washed in PBS 
and serially diluted to achieve a final suspension containing 
10,000 colony forming units (cfu) per mL. Twenty-five AJ 
646 mice (6 to 8 weeks old) were injected intraperitoneally 
(ip) with 100 µL of inocula containing 1000 cfu per mouse. 
After 48 hours of infection, 5 AJ 646 mice per group were 
treated with either D1G (in PBS) or the D1N ip at a recom-
mended dosage of 5 µg g–1 of body weight.17 The dosage 
was repeated twice at intervals of 24 hours, ip for a total 
of 3 doses. At day 2 (post third ip injection), the mice were 
euthanized, the spleens and livers were removed aseptically, 
and the organs were crushed and homogenized for 1 to 2 min 
in the presence of 2 mL of LB broth. Aliquots (500 µL) 
of the organ suspensions were serially diluted in 4.5 mL of 
LB broth to a maximum of 105-fold dilution. Subsequently, 
the dilutions were plated on tryptic soy agar plates, incubated 
overnight at 37°C, and the resulting grey mucoid, discrete 
colonies were counted for plates containing between 30 and 
300 colonies. Also, two groups of Salmonella-infected mice 
(5 mice per group) were administered with either D2G or 
the D2N at a single ip dosage of 15 µg g–1 of body weight 
to determine any concentration-dependent toxicity on the 
kidneys. The mice were euthanized at day 5 of the study 
along with the normally administered dosed mice.
statistical analysis
The mean absorbance in the MTS assay was compared 
between the groups using analysis of variance. The kidney 
scores were compared between the three groups using the 
Kruskal-Wallis Test followed by Dunn’s procedure for 
multiple comparisons. Statistical significance was set to 
alpha = 0.05. Analyses were performed using JMP (ANOVA 
and Kruskal-Wallis test) and SAS (Dunn’s procedure for 
multiple comparisons).
Results
Core-shell nanostructures
DLS showed that polymer-gentamicin core-shell 
nanostructures had a mean intensity average diameter of 
210 (±17) nm and had negligible zeta potentials, ranging 
from –0.7 (±0.2) mv. The amount of gentamicin encapsula-
tion based on a UV spectroscopic analyis of an o-phthalal-
dehyde-mercaptoethanol derivative of the drug showed an 
encapsulation of ∼25%. The rather high drug concentration 
of ∼25% by weight is attributed to strong interactions between 
the cationic gentamicin and the anionic polymer.
In vitro MTs assay
MTS assays conducted on the free gentamicin, copolymer, 
core-shell nanostructure and untreated control showed 
no significant differences in percentage mean absorption 
between various treatments (Figure 2), indicating that the 
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polymers at doses similar to that of the free gentamicin or 
untreated control were non-toxic in vitro.
In vivo toxicity assessment
Based on degrees of inflammation and mineralization of 
kidney tissues, D2N had a median score of 0 (range 0 to 
0.50), untreated control 0 (range 0 to 0.75) and D2G 0.75 
(range 0 to 2.50), determined by compiling the individual 
data scored by the pathologists (Table 1). The Kruskal-Wallis 
statistical test showed that various treatments had a statistically 
significant effect on kidney scores (P = 0.0288). Moreover, 
Dunn’s procedure for multiple comparisons showed that the 
median kidney score for D2G was significantly greater than 
the median kidney score for D2N (P = 0.0223). The other 
two comparisons (D2G vs the untreated control, and the 
untreated control vs D2N) did not differ significantly. 
125 In vitro cytotoxicity assay
100
75
50
25
0
Control
%
 C
el
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y
Free gentamicin Polymer alone Core-shell
nanostructures
Treatment
Figure 2 MTs assay showing the percentage mean absorbance (depicted by % cell viability at wavelength of 490 nm) after incubating  J774A.1 cells with 250 µg mL–1 of core-shell 
nanostructures along with appropriate controls. Results are expressed as means ± sD of 6 measurements. **P  0.05,  ANOVA.
Notes: No significant difference between treatments at P  0.05.
Table 1 Kidney scoring by individual pathologist
Kidney no. Kidney score – D2N Kidney score – untreated Kidney score – D2G
  1st 
pathologist
2nd 
pathologist
1st 
pathologist
  1st 
pathologist
2nd 
pathologist
1 0 0 0 0 2*** 2***
2 0 0 0 0 2*** 2***
3 0 0 1 0 1 1
4 0 0 0* 0* 0 0
5 0 0 1* 0* 0 1
6 0 0 0 0* 1** 1
7 0 0 0 0 0 0
8 0 0 0 0 2*** 0
9 1 0 0 0 0 0
10 0 0 0 0 0 0
Notes: *Mineralization of renal epithelium lining renal papilla collecting ducts.
**Mineralized deposits randomly scattered within the cortex and in medulla.
***Indicates mineralized deposits in the cortex associated with inflammatory cells.
Kidney scores: 0 = normal; 1 = minimal inflammation; 2 = mild inflammation; 3 = moderate inflammation; 4 = marked inflammation.
Abbreviations: D2g, mice group treated with 15 µg g-1 body weight with free gentamicin; D2N, mice group treated with 15 µg g-1 body weight with core shell nanostructure.
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Histopathologically, the D2G-treated kidney tissues revealed 
minimal to mild lymphocytic inflammation associated with 
mineralized deposits (Figure 2). In contrast, the untreated 
or D2N tissues typically showed unremarkable to rare small 
peri-glomerular aggregates of mononuclear cells.
In vivo efficacy
The antibacterial activities of free gentamicin and the core 
shell nanostructures were compared in a S. typhimurium 
infection model in AJ 646 mice. The gentamicin nanostruc-
tures were tested at 2 different dosages, viz. 5 and 15 µg g–1 
to evaluate the efficacy in in vivo bacterial clearance (Table 2). 
D1N resulted in significant reduction of viable bacteria both 
in the liver (0.46 log
10
) and in the spleen (0.25 log
10
) compared 
to the untreated control. However, D1G yielded signifi-
cant reductions of viable bacteria in the liver (0.48 log
10
) 
but not in the spleen relative to those recovered from the 
controls. In contrast, statistically significant reductions in the 
numbers of viable bacteria in the liver (1.03 log
10
) and spleen 
(0.29 log
10
) were observed for the D2N in comparison to the 
D2G and infected control (P  0.05).
Discussion
Aminoglycosides are one of the most commonly used classes 
of antimicrobials against Gram-negative bacteria due to their 
high efficacy and low costs, but they have the potential to 
produce nephrotoxic and ototoxic side effects.19,20 Basically, 
aminoglycosides are low protein-binding drugs that can freely 
filter in the kidney glomeruli upon parenteral administration 
without metabolization in the body. However, around 10% of 
an administered aminoglycoside such as gentamicin can selec-
tively accumulate in kidney tissue and may cause structural 
and functional damage to the renal tubular cells. Thus, 
development of new strategies aiming to prevent their accu-
mulation in the renal tissues is highly desirable for reducing 
toxicity. Also, though aminoglycosides are highly efficacious 
in vitro, their in vivo activity is limited by an inability to 
traverse through the phagocytic cell membrane. This is because 
intracellular penetration of a drug molecule depends on its 
polarity, and polar drugs cannot permeate readily across non-
polar, lipophilic cell membranes. Hence, aminoglycosides such 
as gentamicin which are cationic and polar have relatively low 
permeabilities across cell membranes.18
One means to reduce toxicity and improve efficacy is to 
favor delivery of drugs to the infected organs. In the case of 
systemic infection with S. typhimurium, the target organs of 
infection are the spleen and liver.19 By encapsulating drug 
molecules in polymeric core-shell nanostructures where 
the physico-chemical characteristics of the shell have been 
designed to interact with lipid membranes, internalization by 
the tissue macrophage cells can be improved. This reduces 
transport of free gentamicin to renal tissues and enhances 
targeting to the liver or spleen. In this research, we utilized 
an amphiphilic Pluronic F-68 copolymer as the shell, and 
gentamicin was incorporated into the nanoparticle cores 
through cooperative electrostatic attractions. To fabricate 
the nanostructured complexes, a polyanionic PAA- +Na 
homopolymer10 and PAA- +Na-b-PEO-b-PPO-b-PEO-
b-PAA- +Na block copolymer were co-dissolved and a 
polycationic gentamicin sulfate solution20 was added with 
sonication to form a final one-to-one ratio of anions to cations. 
In general, the polyacrylate components formed the core of the 
complex while the nonionic blocks extended outward into the 
aqueous medium to form the shells, so the polyacrylate homo-
polymer was used to “build up” the sizes and drug loadings of 
the cores as shown schematically in Figure 1. The non-ionic 
polyether shell afforded steric repulsion between particles and 
prevented macroscale agglomeration. The nanostructures pre-
pared via this technique had a drug loading of ∼25% by weight 
of the polymer. However, while the 25% drug loading is high, 
it is noteworthy to observe that a significant amount of the 
charged drug was not incorporated and better understanding 
Table 2 Efficacy cfu (log) reduction of free gentamicin or core-shell nanostructure polymers in liver and spleen from Salmonella-infected 
mouse
Treatment Liver cfu (log) (CI) Liver cfu (log) reduction Spleen cfu (log) (CI) Spleen cfu (log) reduction
Infected control 4.18 (3.98, 4.29) 0.00 3.89 (3.76, 4.28) 0.00
D1N 3.72 (3.28, 3.88) 0.46* 3.64 (3.50, 3.69) 0.25*
D1g 3.70 (3.29, 3.75) 0.48* 3.98 (3.83, 4.01) -0.09
D2N 3.11 (2.99, 3.53) 1.07* 3.60 (3.48, 4.02) 0.29*
D2g 3.95 (3.92, 3.98) 0.23 4.23 (4.13, 4.32) -0.34
*Significantly different from control (P  0.05).
Abbreviations: cfu, coloning forming units; CI, confidence interval; D1N, mice group treated with 5 µg g-1 body weight wiht core shell nanostructure; D2N, mice group treated 
with 15 µg g-1 body weight with core shell nanostructure; D1g, mice group treated with 5 µg g-1 body weight with free gentamicin; D2g, mice group treated with 15 µg g-1 body 
weight with free gentamicin.
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of this issue will be topic for continuing research. Also, 
gentamicin releases from the core-shell nanostructure could 
be a function of cooperativity between the homo and block 
copolymers and drug. This is evidenced from our previous 
findings wherein rate of release of gentamicin from nanostruc-
ture with pluronic F68 shell was relatively slow compared to 
free gentamicin at physiological pH 7.4 and 37°C.14,21 Even 
though the overall complexes had a significant net negative 
charge, they had small zeta potentials in DI water, ranging 
from –0.7 (±0.2) mV. This suggests that the non-ionic PEO 
and PEO-b-PPO-b-PEO shells effectively screened the 
excess of anionic charges in the core from the environment.22 
It has also been suggested that the rate of particle uptake by 
macrophage cells increases with an increase in size with the 
minimum recognizable size of ∼70 to 85 nm.23,24 In our experi-
mental analysis, we observed that the size of the core-shell 
nanostructure was ∼210 (±17) nm but a systematic study of 
the effect of size has not yet been conducted.
The core-shell nanostructures can be potentially realized 
in clinical situations by ruling out any toxicity associated with 
their use in biological systems. This was determined in vitro 
via an MTS assay which measures mitochondrial activity 
through the formation of a soluble formazan product which 
is directly proportional to the number of live cells in culture.25 
MTS assays conducted upon incubation of cells with the core-
shell nanostructures containing gentamicin showed no signifi-
cant differences in absorption compared to untreated control, 
indicating that the polymers at doses similar to that of the 
free gentamicin or untreated control were non-toxic in vitro 
(Figure 2). Further, in vivo studies of renal histopathology 
were performed independently by two anatomic pathologists 
to screen for microscopic lesions. Each kidney was given a 
subjective score from 0 (unremarkable) to 4 (marked). Both 
evaluators noted minimal to mild increased inflammation 
in half of the kidneys in the mice group treated with free 
gentamicin. Additionally, both evaluators noticed mineral 
deposits within the renal cortex associated with inflamma-
tory cells and these lesions were not present in kidneys from 
the untreated or core-shell nanostructure treated groups of 
mice. These lesions are consistent with either the deposition 
of a mineralized substance eliciting inflammation or chronic 
regions of inflammation with dystrophic mineralization. The 
inflammatory infiltrate in these kidneys were predominantly 
comprised of lymphocytes and macrophages, as has been 
similarly observed previously for gentamicin nephrotoxicity.26 
However, the kidneys did not exhibit distended tubules, 
hyaline casts, tubular degeneration, glomerular basement 
membrane alterations or necrosis reported in gentamicin 
toxicity.27,28 Plausibly, the single dose administration of gen-
tamicin at 15 µg g–1 body weight of mice may not have been 
enough to cause concentration dependent toxicity. Repeated 
administration for multiple times/days to the mice similar 
to previous studies may shed more light on the protective 
effects of gentamicin encapsulation against nephrotoxicty.27 
Regardless, unremarkable to minimal renal lesions in 
untreated and core-shell nanostructure-treated mice suggest 
that gentamicin encapsulation may be protective in preventing 
adverse effects in the kidney.
Finally, AJ-646 mice were infected with S. typhimurium 
and treated with the core-shell nanostructures. The results 
indicated that at a 15 µg g–1 dose, free gentamicin was 
ineffective in bacterial clearance. In contrast Salmonella was 
Figure 3 Histopathological microscopic images of kidney tissues of AJ-646 mice euthanized 5 days after intraperitoneal administration:  A) Untreated control group; 
B) D2G-treated group: Minimal to mild lymphocytic inflammation (green arrow) associated with mineralized deposits (orange arrows); C) D2N-treated group:  Typically 
unremarkable to rare small peri-glomerular aggregates of mononuclear cells (arrow).  The tissues were hematoxylin and eosin stained. Scale bar represents 50 µm.
Abbreviations: D2g, mice group treated with 15 µg g-1 body weight with free gentamicin; D2N, mice group treated with 15 µg g-1 body weight with core shell nanostructure.
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reduced significantly in the liver and spleen tissues in the 
D2N treated group. Significant reductions in Salmonella were 
also observed on administration of multiple doses of D1N at 
5 µg g–1 in the spleen and liver and in the liver of D1G-treated 
mice respectively. Previous studies conducted with liposomes 
in an in vivo Salmonella infection model have suggested that 
the gentamicin levels in plasma, liver and spleen are increased 
significantly upon encapsulation.29 This consequently has 
a favorable effect on the bacterial clearance as evidenced 
by 104 reductions in the cfu counts of spleen and liver tissue. 
In addition, encapsulation increases the circulation time of 
the drug, thereby enhancing delivery to the target organ of 
infection and preventing the free drug from reaching the 
renal tissues.30 Furthermore, uptake studies in our laboratory 
have shown that increased amphiphilicity of the gentamicin-
polymer core-shell nanostructure significantly improves the 
amount and rate of uptake by the macrophage cells.21 Thus, 
improved efficacy in Salmonella clearance by the D2N-treated 
mice could be an interplay of both enhanced delivery and 
increased uptake by the tissue macrophage cells.
Altogether, the current study shows that improved 
efficacy and delivery to the infected organs can be achieved 
by incorporating gentamicin in pluronic-based core-
shell structures. This has a protective effect in preventing 
adverse toxic effects on the kidney. Future studies aiming 
to improve the intracellular targeting to the niche where the 
Salmonella reside may enhance the suitability of the core-
shell antimicrobial DDS systems.
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